ESR1 and breast carcinoma: The DATA study, a multicenter phase III study, compared 6 years of anastrozole versus 3 years after 2–3 years of adjuvant tamoxifen in estrogen receptor/progesterone receptor (ER/PR)-positive breast cancer patients who were postmenopausal at randomization.